Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) has been given an average rating of “Buy” by the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $29.42.
A number of brokerages have weighed in on TSHA. Needham & Company LLC reduced their target price on Taysha Gene Therapies to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 17th. Sumitomo Mitsui Financial Group began coverage on Taysha Gene Therapies in a report on Friday, February 18th. They issued an “outperform” rating and a $25.00 target price on the stock. JMP Securities reduced their target price on Taysha Gene Therapies from $44.00 to $36.00 and set a “market outperform” rating on the stock in a report on Friday, April 1st. Robert W. Baird began coverage on Taysha Gene Therapies in a report on Wednesday, March 9th. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, The Goldman Sachs Group reduced their target price on Taysha Gene Therapies from $27.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Taysha Gene Therapies by 75.1% in the 2nd quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $32,000 after acquiring an additional 657 shares in the last quarter. Macquarie Group Ltd. bought a new position in shares of Taysha Gene Therapies in the 3rd quarter worth about $41,000. Citigroup Inc. raised its position in shares of Taysha Gene Therapies by 142.2% in the 3rd quarter. Citigroup Inc. now owns 3,321 shares of the company’s stock worth $62,000 after acquiring an additional 1,950 shares in the last quarter. Sargent Investment Group LLC bought a new position in shares of Taysha Gene Therapies in the 1st quarter worth about $69,000. Finally, Wells Fargo & Company MN bought a new position in shares of Taysha Gene Therapies in the 4th quarter worth about $110,000. 46.05% of the stock is currently owned by hedge funds and other institutional investors.
Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.27). During the same period in the previous year, the company posted ($0.87) earnings per share. Sell-side analysts expect that Taysha Gene Therapies will post -4.01 earnings per share for the current fiscal year.
Taysha Gene Therapies Company Profile (Get Rating)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.